The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
Iproplatin is a second generation metallodrug developed for cancer therapy. Iproplatin binds to and forms DNA crosslinks and platinum-DNA adducts,
resulting in DNA replication failure and cell death. Although less
prone to glutathione inactivation compared to cisplatin, resistance to
this agent has been observed in vitro due to repair of platination
damage by tumor cells.